Sridhar, S., O’Donnell, P. H., Flaig, T. W., Rosenberg, J. E., Hoimes, C. J., Milowsky, M. I., … Moon, H. (2023). 2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC). In Annals of Oncology (Vol. 34, pp. S1203–S1203). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.1014

Sridhar, S., P. H. O’Donnell, T. W. Flaig, J. E. Rosenberg, C. J. Hoimes, M. I. Milowsky, S. Srinivas, et al. “2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC).” In Annals of Oncology, 34:S1203–S1203. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.1014.

Sridhar S, O’Donnell PH, Flaig TW, Rosenberg JE, Hoimes CJ, Milowsky MI, et al. 2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC). In: Annals of Oncology. Elsevier BV; 2023. p. S1203–S1203.

Sridhar, S., et al. “2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC).” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S1203–S1203. Crossref, doi:10.1016/j.annonc.2023.09.1014.

Sridhar S, O’Donnell PH, Flaig TW, Rosenberg JE, Hoimes CJ, Milowsky MI, Srinivas S, George S, McKay RR, Petrylak DP, Coelho Barata PM, Hwang C, Cruz-Correa M, Iafolla M, Mckean M, Dreicer R, Brancato S, Lukas JJ, Yu Y, Moon H. 2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC). Annals of Oncology. Elsevier BV; 2023. p. S1203–S1203.